Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

News | Cardiogenic Shock

September 10, 2012 — Maquet Cardiovascular LLC announced 30-day results from the large, randomized, multicenter intra ...

Home September 10, 2012
Home
Technology

September 10, 2012 — In a recent clinical trial, the Solitaire Flow Restoration Device dramatically outperformed the ...

Home September 10, 2012
Home
Feature

September 7, 2012 — St. Jude Medical Inc. announced results of the FAME II trial demonstrating that patients with fracti ...

Home September 07, 2012
Home
News

September 6, 2012 — Drug-eluting stents (DES) are used less often in women treated with percutaneous coronary ...

Home September 06, 2012
Home
News

September 6, 2012 — Daiichi Sankyo Co. Ltd. and Eli Lilly and Co. announced data from the TRILOGY ACS study, a phase III ...

Home September 06, 2012
Home
Feature

Sept. 4, 2012 — Medtronic has reached two clinical program milestones for its CoreValve transcatheter aortic valve ...

Home September 04, 2012
Home
Technology

September 4, 2012 — Philips Heathcare announced that mVisum Inc.’s STEMI Alert smartphone app is now available to work ...

Home September 04, 2012
Home
News

Sept. 3, 2012  — Due to newly released evidence linking the aftermath of Japan’s 2011 earthquake with an increase in the ...

Home September 04, 2012
Home
Feature

August 30, 2012 — According to Millennium Research Group (MRG), an authority on the medical technology market, as ...

Home August 30, 2012
Home
 An extracted bovine artery with an arteriotomy sealed by a MynxGrip closure dev
Feature | Dave Fornell

Vascular closure devices that use an active method to immediately seal the femoral access site can enable faster patient ...

Home August 29, 2012
Home
The implementation of dedicated access site surveillance and educational program
Feature | Christopher Wilson, D.O.; Kerri Wing, R.N., BSN; Peter Wassmer, M.D., FACC, and Robert Sanchez M.D., FACC

The implementation of dedicated access site surveillance and educational programs, in tandem with pre-existent ...

Home August 29, 2012
Home
Use of transradial access for PCI can increase radiation exposure.
Feature | Radial Access | Mladen I. Vidovich, M.D., FACC, FSCAI

Recently, concerns have been raised that transradial (TR) cardiac catheterization significantly increases radiation ...

Home August 28, 2012
Home
Verifynow platelet testing clopidogrel nonresponders
Feature | Nicole Fornell, Pharm D

A major issue with clopidogrel is that one-third of patients are nonresponders because they lack the enzymes to ...

Home August 28, 2012
Home
Ticagrelor, Brillinta, is the newest antiplatelet agent on the market. Ticagrelor is a reversible nonthienopyridine P2Y12 receptor antagonist that prevents signal transduction and platelet activation.
Feature | Antiplatelet and Anticoagulation Therapies | Nicole Fornell, Pharm D

The standard-of-care for dual antiplatelet therapy (DAPT) for more than a decade has been clopidogrel (Plavix) plus ...

Home August 28, 2012
Home
Feature

August 23, 2012 — Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that ...

Home August 23, 2012
Home
Subscribe Now